Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

70.47 +0.45 (+0.65%)
Streaming Delayed Price Updated: 11:57 AM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
54 55 Next >
FDA Approval For AstraZeneca - Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
US Study Shows Omicron As Severe As Previous COVID Variants: Reuters
Via Benzinga
FDA Accepts AstraZeneca's sBLA for Imfinzi (durvalumab) in biliary tract cancer (BTC) with Priority Review
The U.S. Food and Drug Administration (FDA) has accepted AstraZeneca's (NASDAQ: AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care... 
Via Benzinga
AstraZeneca's Imfinzi/Chemo Combo Goes Under Priority FDA Review For Bile Duct Cancer
Via Benzinga
The Global Cancer immunotherapy market is expected to reach 152 Billion by 2024 led by Astra Zeneca Nasdaq: AZN; Celgene Corp. (NASDAQ: CELG) Including Late Stage Newcomer; Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)
Via Viz Release
Fourth COVID-19 Shot? See Why Medical Professionals Are Skeptical
Medical professionals are undecided on whether a fourth dose of the Covid-19 vaccine would benefit the wider population, as countries are beginning to offer the fourth dose to vulnerable groups. 
Via Benzinga
4 Healthcare Funds With "Double Discounts"
There's nothing that closed-end fund investors love more than finding a smartly run fund in an unfairly beaten-down sector. This hands us a nice discount plus a much bigger dividend. Let's take a look... 
Via Talk Markets
Read Why This Analyst Is 'Encouraged' By Seagen's Q1 Sales
Following Seagen Inc's (NASDAQ: SGEN) 1Q22 earnings release, RBC Capital Markets is encouraged by the quarterly sales of the product portfolio in light of previously set cautious guidance. 
Via Benzinga
Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review
The Nasdaq hit its lowest level since 2020. Apple and Facebook led key earnings. 
Via Investor's Business Daily
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
AstraZeneca: Q1 Earnings Insights
AstraZeneca (NASDAQ:AZN) reported its Q1 earnings results on Friday, April 29, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings AstraZeneca reported an EPS of... 
Via Benzinga
AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook
Via Benzinga
A Peek Into The Markets: US Stock Futures Down; Apple Tops Q2 Views
Pre-open movers 
Via Benzinga
Earnings Scheduled For April 29, 2022
Companies Reporting Before The Bell • Weyerhaeuser (NYSE:WY) is projected to report quarterly earnings at $1.19 per share on revenue of $2.93 billion. 
Via Benzinga
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Six US States Probing Mysterious Liver Inflammation In Kids: Bloomberg
At least six U.S. states are reporting confirmed or suspected cases of an unexplained, severe liver disorder in children. Health officials in New York state and Wisconsin said they’re investigating... 
Via Benzinga
Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer
Via Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
3 Biotech Stocks Under $10 to Add to Your Buy List
These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. 
Via InvestorPlace
How To Attend AstraZeneca Q1 2022 Earnings Conference Call
AstraZeneca (NASDAQ:AZN) will host a conference call at 06:45 AM ET on April 29, 2022, to discuss Q1 2022 earnings results. How to Attend AstraZeneca (AZN) Conference Call Follow this link to access... 
Via Benzinga
Valneva Receives More Questions From European Regulator For Its COVID-19 Vaccine, Shares Fall
Via Benzinga
AstraZeneca's Tremelimumab/Imfinzi Combo Regime Goes Under Priority FDA Review For Liver Cancer
Via Benzinga
Week In Review: Wuhan Binhui Raises $47 Million For Oncolytic Virus Products
Wuhan Binhui Biotech closed a $47 million Series B financing to support its R&D of oncolytic virus products. Trevena, a Philadelphia-area CNS biopharma, closed a $40 million revenue-based financing... 
Via Talk Markets
World's Largest Vaccine Manufacturer Stops Making COVID-19 Vaccines As 200M Doses Pile-Up: Bloomberg
Serum Institute of India Ltd, the world’s largest vaccine manufacturer, has stopped making new batches of COVID-19 shots after its stockpile grew to 200 million doses amid a global supply glut, 
Via Benzinga
Public-health Authorities in US, UK, Probe Mysterious Cases Of Severe Hepatitis In Young Kids: WSJ
Via Benzinga
If You Invested $100 In AstraZeneca 5 Years Ago, Here's How Much You Would Have Today
AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 4.24% on an annualized basis producing an average annual return of 17.72%. Currently, AstraZeneca has a market... 
Via Benzinga
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Jim Cramer Gives His Opinion On AstraZeneca, Intuitive Surgical And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Uranium Energy Corp. (NYSE: UEC) is a "very speculative stock." He added that the stock had a very big run and might get "cut in half or double. 
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company. 
Via InvestorPlace
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.